Home / Recalls / PharMEDium Services, LLC. / D-0080-2018

D-0080-2018 Class II Terminated

Recalled by PharMEDium Services, LLC. — Memphis, TN

FDA drug recall D-0080-2018 was initiated by PharMEDium Services, LLC. on October 13, 2017 and is designated Class II. Reason for recall: Superpotent drug: out of specification result for potency The recall status is terminated (terminated January 24, 2020). Affected quantity: 499 syringes.

Recall Details

Product Type
Drugs
Report Date
November 22, 2017
Initiation Date
October 13, 2017
Termination Date
January 24, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
499 syringes

Product Description

Hydromorphone HCl 0.5 mg per mL in 0.9% Sodium Chloride Injection 1 mL, packaged in syringes, Rx Only , PharMEDium Services, LLC. 913 N. Davis Ave Cleveland, MS 38732, NDC 61553-352-40

Reason for Recall

Superpotent drug: out of specification result for potency

Distribution Pattern

CA, IL

Code Information

Lot#: 172820134M, Exp 01/18

Other recalls by PharMEDium Services, LLC.

  • D-1086-2020 Class II — succinylcholine Chloride, 20 mg per 5 mL, 100 mg per 5 mL, 5 mL BD Syringe, For (March 16, 2020)
  • D-1081-2020 Class II — ePHEDrine Sulfate, 5 mg per mL, 50 mg per 10 mL, In 0.9% Sodium Chloride 10 mL (March 16, 2020)
  • D-1091-2020 Class II — ePHEDrine Sulfate 10 mg per mL 50 mg per 5 mL in 0.9% 5 mL Sodium Chloride 5 (March 16, 2020)
  • D-1085-2020 Class II — fentaNYL Citrate 10 mcg per mL, 2,500 mcg per 250 mL, 250 mL in a LifeCare Bag, (March 16, 2020)
  • D-1092-2020 Class II — fentaNYL Citrate Injection, 50 mcg per mL, 250 mcg per 5 mL 5 mL syringe, For I (March 16, 2020)
  • D-1089-2020 Class II — fentaNYL Citrate 50 mcg per mL, (Preservative Free) Injection, For IV use, 1,500 (March 16, 2020)
  • D-1083-2020 Class II — rocuronium Bromide 10 mg per mL 50 mg per 5 mL, 5 mL BD Syringe, For IV Use, Ph (March 16, 2020)
  • D-1088-2020 Class II — ePHEDrine Sulfate, 5 mg per mL, 25 mg per 5 mL in 0.9% Sodium Chloride, 5 mL sy (March 16, 2020)
  • D-1084-2020 Class II — HYDROmorphone in 0.9% Sodium Chloride HCl, 1 mg per mL, For IV Use, 30 mg per 30 (March 16, 2020)
  • D-1082-2020 Class II — nICARdipine HCl (0.1 mg/mL) 1 mg/10mL, in 0.9% Sodium Chloride Injection USP, 1 (March 16, 2020)

FDA data resources